• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

骨关节炎:机制与治疗进展

Osteoarthritis: Mechanisms and Therapeutic Advances.

作者信息

Liu Wei, Guo Ning-Yi, Wang Jian-Quan, Xu Bing-Bing

机构信息

Department of Sports Medicine Peking University Third Hospital, Institute of Sports Medicine of Peking University Beijing China.

Beijing Key Laboratory of Sports Injuries Beijing China.

出版信息

MedComm (2020). 2025 Aug 1;6(8):e70290. doi: 10.1002/mco2.70290. eCollection 2025 Aug.

DOI:10.1002/mco2.70290
PMID:40757100
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12314552/
Abstract

Osteoarthritis (OA) is a chronic joint disease characterized by a complex pathological mechanism, including chondrocyte dysfunction, synovial inflammation, subchondral bone remodeling, and molecular regulation abnormalities. Key signaling pathways such as nuclear factor-κB, mitoase-activated protein kinase, and transforming growth factor-β are disrupted, leading to cytokine imbalance, oxidative stress, and excessive protease activity, which collectively contribute to cartilage degeneration. This review summarizes the potential causes of OA, focusing on cellular and structural abnormalities in cartilage, synovial tissue, and subchondral bone, as well as dysregulation of signaling pathways, gene regulation, and molecular mechanisms. Given the limitations of current diagnostic methods for OA, biomarkers may offer new hope. Emerging therapeutic strategies for OA include biologics, intelligent drug delivery, and tissue engineering, aiming to modulate the immune microenvironment while promoting cartilage repair. However, these approaches face challenges such as long-term safety and scalability. Future research may require deeper multidisciplinary collaboration and combination therapies to revolutionize the management of OA and improve patient outcomes.

摘要

骨关节炎(OA)是一种慢性关节疾病,其病理机制复杂,包括软骨细胞功能障碍、滑膜炎症、软骨下骨重塑和分子调节异常。核因子-κB、丝裂原活化蛋白激酶和转化生长因子-β等关键信号通路被破坏,导致细胞因子失衡、氧化应激和蛋白酶活性过高,这些共同导致软骨退变。本综述总结了OA的潜在病因,重点关注软骨、滑膜组织和软骨下骨的细胞和结构异常,以及信号通路失调、基因调控和分子机制。鉴于目前OA诊断方法的局限性,生物标志物可能带来新的希望。OA的新兴治疗策略包括生物制剂、智能药物递送和组织工程,旨在调节免疫微环境同时促进软骨修复。然而,这些方法面临长期安全性和可扩展性等挑战。未来的研究可能需要更深入的多学科合作和联合治疗,以彻底改变OA的管理并改善患者预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eefd/12314552/f651dcef32bc/MCO2-6-e70290-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eefd/12314552/6efefb5dc92d/MCO2-6-e70290-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eefd/12314552/d925c369de0e/MCO2-6-e70290-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eefd/12314552/7e988212661b/MCO2-6-e70290-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eefd/12314552/b616f3e8ac48/MCO2-6-e70290-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eefd/12314552/a3f8007ab05c/MCO2-6-e70290-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eefd/12314552/1023f8248564/MCO2-6-e70290-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eefd/12314552/f651dcef32bc/MCO2-6-e70290-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eefd/12314552/6efefb5dc92d/MCO2-6-e70290-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eefd/12314552/d925c369de0e/MCO2-6-e70290-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eefd/12314552/7e988212661b/MCO2-6-e70290-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eefd/12314552/b616f3e8ac48/MCO2-6-e70290-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eefd/12314552/a3f8007ab05c/MCO2-6-e70290-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eefd/12314552/1023f8248564/MCO2-6-e70290-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eefd/12314552/f651dcef32bc/MCO2-6-e70290-g006.jpg

相似文献

1
Osteoarthritis: Mechanisms and Therapeutic Advances.骨关节炎:机制与治疗进展
MedComm (2020). 2025 Aug 1;6(8):e70290. doi: 10.1002/mco2.70290. eCollection 2025 Aug.
2
Osteoarthritis in cats: what we know, and mostly, what we don't know. . . yet.猫的骨关节炎:我们所知道的,以及大多数情况下,我们还不知道的…… 目前。
J Feline Med Surg. 2025 Jul;27(7):1098612X251347999. doi: 10.1177/1098612X251347999. Epub 2025 Jul 20.
3
Transformative approaches for effective clinical trials to reduce the disease burden of osteoarthritis.开展有效临床试验以减轻骨关节炎疾病负担的变革性方法。
Semin Arthritis Rheum. 2025 Apr;71:152652. doi: 10.1016/j.semarthrit.2025.152652. Epub 2025 Feb 3.
4
Ultrasound Phenotype-Based Approach to Treatment Choice in Osteoarthritis.基于超声表型的骨关节炎治疗选择方法
Life (Basel). 2025 Jul 19;15(7):1140. doi: 10.3390/life15071140.
5
Gene therapy pipelines for osteoarthritis: current innovations, operational challenges, and future directions.骨关节炎的基因治疗管线:当前创新、操作挑战及未来方向
Connect Tissue Res. 2025 Jul 4:1-8. doi: 10.1080/03008207.2025.2520319.
6
In vitro and in vivo delivery of mRNA to joint cells using polymeric nanoparticles.使用聚合物纳米颗粒在体外和体内将mRNA递送至关节细胞。
Acta Biomater. 2025 Jun 24. doi: 10.1016/j.actbio.2025.06.039.
7
Management of urinary stones by experts in stone disease (ESD 2025).结石病专家对尿路结石的管理(2025年结石病专家共识)
Arch Ital Urol Androl. 2025 Jun 30;97(2):14085. doi: 10.4081/aiua.2025.14085.
8
Vitamin D Alleviates Osteoarthritis Progression by Targeting Cartilage and Subchondral Bone via Myd88-TAK1-ERK Axis Suppression.维生素D通过抑制Myd88-TAK1-ERK轴靶向软骨和软骨下骨减轻骨关节炎进展。
Drug Des Devel Ther. 2025 Jul 8;19:5855-5870. doi: 10.2147/DDDT.S526064. eCollection 2025.
9
Recent advances in platelet-rich plasma therapy for osteoarthritis: mechanisms and clinical efficacy.富血小板血浆治疗骨关节炎的最新进展:作用机制与临床疗效
J Mater Chem B. 2025 Jul 30;13(30):9001-9022. doi: 10.1039/d5tb00394f.
10
Exploration of bioactive variants of the BMP7-derived p[63-82] peptide for ameliorating the OA-associated chondrocyte phenotype.探索BMP7衍生的p[63-82]肽的生物活性变体以改善骨关节炎相关软骨细胞表型。
Arthritis Res Ther. 2025 Jul 30;27(1):161. doi: 10.1186/s13075-025-03599-4.

引用本文的文献

1
Analysis of potential molecular targets and mechanisms of brominated flame retardants in causing osteoarthritis using network toxicology, machine learning, SHAP analysis, and molecular dynamics simulation.利用网络毒理学、机器学习、SHAP分析和分子动力学模拟分析溴化阻燃剂导致骨关节炎的潜在分子靶点和机制。
BMC Pharmacol Toxicol. 2025 Aug 18;26(1):150. doi: 10.1186/s40360-025-00990-4.

本文引用的文献

1
Circulating miR-126-3p is a mechanistic biomarker for knee osteoarthritis.循环中的miR-126-3p是膝关节骨关节炎的一种机制性生物标志物。
Nat Commun. 2025 Feb 27;16(1):2021. doi: 10.1038/s41467-025-57308-5.
2
Extracecellulr vesicles (EVs) microRNAs (miRNAs) derived from mesenchymal stem cells (MSCs) in osteoarthritis (OA); detailed role in pathogenesis and possible therapeutics.骨关节炎(OA)中间充质干细胞(MSC)来源的细胞外囊泡(EV)微小RNA(miRNA);在发病机制中的详细作用及可能的治疗方法。
Heliyon. 2025 Jan 27;11(3):e42258. doi: 10.1016/j.heliyon.2025.e42258. eCollection 2025 Feb 15.
3
Bio-3D printing of scaffold-free ADSC-derived cartilage constructs comparable to natural cartilage in vitro.
体外生物3D打印无支架的脂肪来源干细胞衍生软骨构建体,其性能与天然软骨相当。
J Orthop Surg Res. 2025 Feb 20;20(1):182. doi: 10.1186/s13018-025-05604-7.
4
Osteoarthritis.骨关节炎
Nat Rev Dis Primers. 2025 Feb 13;11(1):10. doi: 10.1038/s41572-025-00594-6.
5
Development and Characterization of Magnetic Nanoemulsion-Based Senolytic Peptides for Osteoarthritis Treatment.用于骨关节炎治疗的基于磁性纳米乳液的衰老细胞裂解肽的研发与表征
Int J Mol Sci. 2025 Feb 3;26(3):1292. doi: 10.3390/ijms26031292.
6
Therapeutic potential of SOX family transcription factors in osteoarthritis.SOX家族转录因子在骨关节炎中的治疗潜力
Ann Med. 2025 Dec;57(1):2457520. doi: 10.1080/07853890.2025.2457520. Epub 2025 Jan 31.
7
Intra-Articular Injection of Human Bone Marrow-Derived Mesenchymal Stem Cells in Knee Osteoarthritis: A Randomized, Double-Blind, Controlled Trial.人骨髓间充质干细胞关节腔内注射治疗膝关节骨关节炎:一项随机、双盲、对照试验
Cell Transplant. 2025 Jan-Dec;34:9636897241303275. doi: 10.1177/09636897241303275.
8
Co-delivery of IL-1Ra and SOX9 via AAV inhibits inflammation and promotes cartilage repair in surgically induced osteoarthritis animal models.通过腺相关病毒共同递送白细胞介素-1受体拮抗剂(IL-1Ra)和SOX9可抑制手术诱导的骨关节炎动物模型中的炎症并促进软骨修复。
Gene Ther. 2025 Jan 20. doi: 10.1038/s41434-025-00515-y.
9
Safety and efficacy of mesenchymal stromal cells mitochondria transplantation as a cell-free therapy for osteoarthritis.间充质基质细胞线粒体移植作为骨关节炎无细胞疗法的安全性和有效性
J Transl Med. 2025 Jan 7;23(1):26. doi: 10.1186/s12967-024-05945-7.
10
The Intra-Articular Delivery of a Low-Dose Adeno-Associated Virus-IL-1 Receptor Antagonist Vector Alleviates the Progress of Arthritis in an Osteoarthritis Rat Model.低剂量腺相关病毒-白细胞介素-1受体拮抗剂载体的关节内递送可减轻骨关节炎大鼠模型中关节炎的进展。
Pharmaceutics. 2024 Nov 25;16(12):1518. doi: 10.3390/pharmaceutics16121518.